Flagship Pioneering and Quotient Therapeutics have entered a strategic partnership with Pfizer to identify new therapeutic targets for cardiovascular and renal diseases.

The companies will focus on two research programmes to analyse somatic mutations in diseased tissue.

This could lead to the discovery and development of new treatments in the cardiovascular and renal disease fields.

Quotient Therapeutics co-founder and CEO, and Flagship Pioneering origination partner Jacob Rubens stated: “Quotient’s Somatic Genomics platform explores the extensive genetic diversity within the 30 trillion cells inside our body. This offers an incredibly rich and unchartered territory for drug discovery. 

​“These two research programmes will deploy our unique platform capabilities to identify novel links between genes and cardiovascular or renal disease, which are leading causes of mortality and morbidity around the world.” 

Flagship’s in-house drug development unit, Pioneering Medicines, is tasked with spearheading this initiative.

Pioneering will spearhead the discovery process to identify new drug development projects, leveraging Flagship's multiple bioplatforms.

The agreement with Quotient represents the latest endeavour under the strategic partnership between Flagship and Pfizer, initially signed in July 2023.

Flagship Pioneering and Pfizer agreed to focus on developing a new therapy pipeline.

The parties agreed to invest $50m each to assess prospects for developing ten single-asset programmes.

Pfizer internal medicine research unit chief scientific officer Bill Sessa stated: “This strategic collaboration with Flagship provides an opportunity to explore early discovery work with Quotient’s proprietary platform to potentially unlock new targets for cardiovascular and renal disease.

“With our deep cardiometabolic heritage, we will continue to push the boundaries of research innovation to help address significant gaps in care that remain for these patients.”